Matching articles for "Glucose monitoring devices"

Minimed 670G: A Hybrid Closed-Loop Insulin Delivery System

   
The Medical Letter on Drugs and Therapeutics • November 21, 2016;  (Issue 1508)
The FDA has approved the Minimed 670G (Medtronic), a hybrid closed-loop insulin delivery system for use in patients ≥14 years old with type 1 diabetes. The system uses an algorithm to automatically adjust...
The FDA has approved the Minimed 670G (Medtronic), a hybrid closed-loop insulin delivery system for use in patients ≥14 years old with type 1 diabetes. The system uses an algorithm to automatically adjust basal insulin doses based on readings from a continuous glucose monitor (CGM). It fully automates basal insulin delivery in "auto" mode, but is considered a "hybrid" system (not a true "artificial pancreas") because it requires some action by the patient. The 670G system is expected to become available in Spring 2017.
Med Lett Drugs Ther. 2016 Nov 21;58(1508):147-8 | Show Full IntroductionHide Full Introduction

MiniMed 530G: An Insulin Pump with Low-Glucose Suspend Automation

   
The Medical Letter on Drugs and Therapeutics • December 9, 2013;  (Issue 1431)
The FDA has approved the MiniMed 530G (Medtronic), an insulin pump used in combination with a continuous glucose monitoring sensor (Enlite) that can stop delivery of insulin when interstitial...
The FDA has approved the MiniMed 530G (Medtronic), an insulin pump used in combination with a continuous glucose monitoring sensor (Enlite) that can stop delivery of insulin when interstitial glucose reaches a prespecified low level. It is the only sensoraugmented insulin pump available in the US with this capability.
Med Lett Drugs Ther. 2013 Dec 9;55(1431):97-8 | Show Full IntroductionHide Full Introduction

Continuous Glucose Monitoring

   
The Medical Letter on Drugs and Therapeutics • May 2, 2011;  (Issue 1363)
A variety of continuous glucose monitoring (CGM) devices have been used in an effort to reduce the hypoglycemia and wide glucose excursions that complicate insulin treatment of diabetes. Since the last...
A variety of continuous glucose monitoring (CGM) devices have been used in an effort to reduce the hypoglycemia and wide glucose excursions that complicate insulin treatment of diabetes. Since the last Medical Letter issue reviewing such devices, some new devices and some new data on old devices have become available. The devices currently marketed in the US for personal use are listed in Table 1.
Med Lett Drugs Ther. 2011 May 2;53(1363):35-6 | Show Full IntroductionHide Full Introduction

Continuous Glucose Monitoring

   
The Medical Letter on Drugs and Therapeutics • February 12, 2007;  (Issue 1254)
A variety of glucose monitoring devices have been used in an effort to reduce the hypoglycemia and wide glucose excursions that complicate insulin treatment of diabetes. Since the last Medical Letter issue...
A variety of glucose monitoring devices have been used in an effort to reduce the hypoglycemia and wide glucose excursions that complicate insulin treatment of diabetes. Since the last Medical Letter issue reviewing such devices, more continuous glucose monitoring (CGM) systems have become available. Five devices available now, and two expected to be marketed soon, are listed in the table on page 14. The FDA has approved continuous glucose devices only for the observation of glucose trends.
Med Lett Drugs Ther. 2007 Feb 12;49(1254):13-5 | Show Full IntroductionHide Full Introduction

New Glucose-monitoring Technologies

   
The Medical Letter on Drugs and Therapeutics • December 8, 2003;  (Issue 1171)
Improved glucose meters and 2 sensing systems for continuous monitoring have become available for management of...
Improved glucose meters and 2 sensing systems for continuous monitoring have become available for management of diabetes.
Med Lett Drugs Ther. 2003 Dec 8;45(1171):98-100 | Show Full IntroductionHide Full Introduction

GlucoWatch Biographer: A Noninvasive Glucose Monitoring Device

   
The Medical Letter on Drugs and Therapeutics • May 14, 2001;  (Issue 1104)
An automatic, noninvasive, glucose-monitoring device (GlucoWatch Biographer) has been approved for marketing by the FDA. The manufacturer states that it is not meant to replace a regular blood glucose...
An automatic, noninvasive, glucose-monitoring device (GlucoWatch Biographer) has been approved for marketing by the FDA. The manufacturer states that it is not meant to replace a regular blood glucose meter.
Med Lett Drugs Ther. 2001 May 14;43(1104):42 | Show Full IntroductionHide Full Introduction